EXG34217

· Elixirgen Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for EXG34217, covering 2026-02-06 to 2026-02-06. Get the full timeline:

Most recent: Clinical Trial Update: Study to Evaluate of EXG34217 in Patients With Telomere Biology Disorders With Bone Marrow Failure [Phase 1]